NCT05117632

ALTO-100 in MDD and/or PTSD

An Open-label Study of ALTO-100 in Adults With Major Depressive Disorder and/or Post-traumatic Stress Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 245 (actual)
• Sponsor: Alto Neuroscience · Industry
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.

Conditions

• Major Depressive Disorder
• Post Traumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	ALTO-100 PO tablet	one tablet twice daily

Timeline

• Start date: 2021-12-20
• Primary completion: 2022-12-01
• Completion: 2022-12-09
• First posted: 2021-11-11
• Last updated: 2023-12-01

Locations

23 sites across 1 country: United States

Regulatory

• FDA-regulated drug study